# Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

> **NCT02475382** · — · NO_LONGER_AVAILABLE · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Squamous Non-Small Cell Lung Cancer
- Non-squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02475382
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475382, "Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02475382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*